B

Biohit Oyj
OMXH:BIOBV

Watchlist Manager
Biohit Oyj
OMXH:BIOBV
Watchlist
Price: 2.3 EUR Market Closed
Market Cap: 34.8m EUR
Have any thoughts about
Biohit Oyj?
Write Note

Biohit Oyj
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Biohit Oyj
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
B
Biohit Oyj
OMXH:BIOBV
Capital Expenditures
-€348k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-2%
R
Revenio Group Oyj
OMXH:REG1V
Capital Expenditures
-€4.2m
CAGR 3-Years
-36%
CAGR 5-Years
-23%
CAGR 10-Years
-27%
M
Modulight Oyj
OMXH:MODU
Capital Expenditures
-€15.7m
CAGR 3-Years
-97%
CAGR 5-Years
-64%
CAGR 10-Years
N/A
B
Bioretec Oy
OMXH:BRETEC
Capital Expenditures
-€161.4k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
O
Optomed Oyj
OMXH:OPTOMED
Capital Expenditures
-€2.4m
CAGR 3-Years
-10%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
N
Nexstim Oyj
OMXH:NXTMH
Capital Expenditures
-€1.6m
CAGR 3-Years
-44%
CAGR 5-Years
-16%
CAGR 10-Years
N/A
No Stocks Found

Biohit Oyj
Glance View

Market Cap
34.9m EUR
Industry
Health Care

Biohit Oyj engages in the development, manufacture, and market of diagnostic tests and analysis systems. The company is headquartered in Helsinki, Etela-Suomen. The firm operates one business segment, named Diagnostics. The Diagnostics segment offers solutions for the early diagnosis and prevention of gastrointestinal diseases. The company provides blood-sample examination based on GastroPanel for the diagnosis of stomach illnesses and associated risks, quick tests for the diagnosis of lactose intolerance and Helicobacter pylori infection in connection with gastroscopy, as well as the ColonView examination for the early detection of fecal occult intestinal bleeding, which indicates a risk of colorectal cancer. The Company’s products are used in hospitals, healthcare centers and research institutions. The company operates primarily in Europe and Asia. Furthermore, the Company is a parent of Biohit Healthcare Ltd, Biohit Healthcare Srl, Oy Finio Ab, and Vantaan Hienomekano Oy, among others.

BIOBV Intrinsic Value
3.35 EUR
Undervaluation 31%
Intrinsic Value
Price
B

See Also

What is Biohit Oyj's Capital Expenditures?
Capital Expenditures
-348k EUR

Based on the financial report for Jun 30, 2024, Biohit Oyj's Capital Expenditures amounts to -348k EUR.

What is Biohit Oyj's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-2%

Over the last year, the Capital Expenditures growth was -119%.

Back to Top